PHARMACOKINETICS OF NEW CEPHALOSPORINS

新型头孢菌素药代动力学

• 批准号: 7349813
• 负责人: Robert E LANFORD
• 金额: $ 0.04万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7349813
• 关键词: PHARMACOKINETICS; NEW; CEPHALOSPORINS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. New antibiotics are constantly needed to treat infections with antibiotic resistant organisms. Cephalosporins need to be tested for bioavailability in chimpanzees, because there is a serum binding protein in humans and chimpanzees that limits availability. Thus, a pharmacokinetic study in chimpanzees predicts the level of antibiotic with which to initiate human trials. The proposed experiment will involve testing of 4 new cephalosporin compounds in 2 same-sex chimpanzees of similar weight. Compounds will be given IV every two weeks at a dose of 0.5 mg/kg. each dosing will involve the following blood sampling times; 0 or immediately prior to the dose, 15 min., 30 min., 1 hr., 2 hrs., 4 hrs., 8 hrs. and 24 hrs. Plasma samples will be tested for drug levels to determine the pharmacokinetics of these new drugs.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。不断需要新的抗生素来治疗抗生素耐药菌感染。需要对头孢菌素在黑猩猩中的生物利用度进行测试，因为人类和黑猩猩的血清结合蛋白限制了其可用性。因此，在黑猩猩身上进行的药代动力学研究可以预测抗生素的水平，从而启动人体试验。拟议的实验将包括在2只体重相似的同性黑猩猩身上测试4种新的头孢菌素化合物。每两周静脉给药，剂量为0.5 mg/kg。每次给药将涉及以下血液采样次数；在给药前0或立即，15分钟，30分钟，1小时。2小时。4小时。8小时。24小时。将对血浆样本进行药物水平测试，以确定这些新药的药代动力学。